On Thursday, Shares of Charles Schwab Corp (NYSE:SCHW), gained 0.71% to $28.33.
Charles Schwab Investment Administration recently declared planned changes to its money market fund line-up.
To address new SEC regulations, all Schwab Prime and Municipal Money Market Funds plan to qualify as retail money market funds by October 14, 2016. As such, these funds will continue to seek to maintain a constant net asset value (NAV) of $1.00 per share, and will be subject to potential liquidity fees and redemption gates in times of extreme market volatility.
Schwab’s Government Money Funds and the Schwab Money Market Portfolio will be officially designated as government money market funds under the SEC’s new definition of such funds on April 14, 2016, and as a result, they will continue to seek to maintain a constant NAV of $1.00 per share. These funds have no plans to adopt a policy to implement liquidity fees or redemption gates at this time.
The Charles Schwab Corporation, through its auxiliaries, provides wealth administration, securities brokerage, banking, money administration, and financial advisory services. The company operates through two segments, Investor Services and Advisor Services.
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX), inclined 12.00% to $43.60, during its last trading session.
Neurocrine Biosciences, declared that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically noteworthy reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial comprised moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
The pre-specified primary efficacy endpoint was the change-from-baseline in the Abnormal Involuntary Movement Scale (AIMS) at Week 6 in the 80mg once-daily dosing group contrast to placebo as assessed by central blinded video raters. The AIMS ratings at Week 6 for the 80mg once-daily NBI-98854 intention-to-treat (ITT) population was reduced 3.1 points (Least-Squares Mean) more than placebo.
“We are very happy with the outstanding efficacy and side effect profile demonstrated by NBI-98854 in the Kinect 3 study. The efficacy data from this pivotal Phase III study completes our placebo-controlled dataset for NBI-98854 in tardive dyskinesia,” said Kevin C. Gorman, President and Chief Executive Officer of Neurocrine. “We will now turn our focus to concluding the open-label safety portion of the studies in tardive dyskinesia patients and compiling the data for both doses of NBI-98854 to be comprised in the New Drug Application we intend to file with the FDA in 2016.” Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage comprise elagolix, which is in Phase III study for endometriosis; elagolix that is in Phase IIb study for uterine fibroids; Corticotropin-Releasing Factor Receptor1 Antagonist, which is in Phase I/II study for congenital adrenal hyperplasia and stress-related disorders; and Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that is in Phase III study for movement disorders, in addition to Phase I study for tourette syndrome. Its research programs comprise VMAT2 for movement disorders, bipolar disorders, and schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for mens and womens health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other conditions.
Finally, National-Oilwell Varco, Inc. (NYSE:NOV), ended its last trade with 0.74% gain, and closed at $40.77.
National-Oilwell Varco, has revealed insider buying and selling activities to the Securities Exchange, The director, of National Oilwell Varco Inc, Armstrong Greg L had unloaded 5,736 shares at $54.49 per share in a transaction on April 30, 2015. The total value of transaction was $312,555. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
National Oilwell Varco, Inc. designs, manufactures, and sells equipment and components used in oil and gas drilling, completion, and production; and provides oilfield services to the upstream oil and gas industry worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
